Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) presents a growing global health challenge with increasing mortality rates.
• Diagnosis often occurs at advanced stages, necessitating effective systemic therapies.
• Current treatments include modified FOLFIRINOX or nab-paclitaxel and gemcitabine, with considerations for dose modification in elderly patients.

Purpose of the Study:

• To review current and emerging therapeutic strategies for advanced pancreatic ductal adenocarcinoma (PDAC).
• To highlight the importance of maintenance therapy, targeted agents, and supportive care in PDAC management.
• To discuss the role of novel agents and supportive interventions in improving patient outcomes.

Main Methods:

• Review of current systemic therapies for PDAC, including combination chemotherapy.
• Evaluation of maintenance therapy strategies, including the role of olaparib in BRCA-mutated PDAC.
• Discussion of supportive care measures such as pancreatic enzyme replacement therapy (PERT) and management of small intestinal bacterial overgrowth (SIBO).
• Assessment of thromboprophylaxis with rivaroxaban in advanced PDAC.

Main Results:

• Olaparib demonstrated a 3.6-month progression-free survival benefit in a subset of PDAC patients with germline BRCA1/2 mutations.
• Pancreatic enzyme replacement therapy (PERT) is often underutilized despite potential benefits.
• Small intestinal bacterial overgrowth (SIBO) is common in PDAC patients and contributes to symptoms like bloating and diarrhea.
• Rivaroxaban use was linked to reduced thrombosis risk without increased major bleeding in advanced PDAC patients on systemic therapy.

Conclusions:

• Maintenance therapy, including olaparib for specific mutations, should be considered for PDAC patients.
• Optimizing pancreatic enzyme replacement therapy (PERT) and addressing small intestinal bacterial overgrowth (SIBO) are crucial supportive care aspects.
• Rivaroxaban may be beneficial for thrombosis prevention in advanced PDAC patients undergoing systemic treatment.